GT Medical Technologies
GT Medical Technologies Raises $100M Series E for Brain Tumor Radiotherapy Implant
GT Medical Technologies announced $100M in Series E financing on June 9, 2026. GT Medical Technologies raised a $100 million Series E led by new investor Viking Global Investors to accelerate commercial and operational initiatives for its GammaTile brain tumor therapy.
Round details
The financing includes backing from Viking Global Investors, MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, FemHealth Ventures. The company did not publish a valuation with the announcement.
- Round: Series E
- Capital announced: $100M
How the company plans to use the capital
GT Medical Technologies said the funds will accelerate investments across commercial and operational initiatives, and will also support continued expansion of its recently initiated BRIDGES randomized controlled trial in newly diagnosed glioblastomas.
Why this matters for GTM teams
The round was led by a new investor, Viking Global Investors, with participation from existing investors, and the company said the funds will go toward commercial and operational initiatives and expansion of its BRIDGES randomized controlled trial.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: GT Medical Technologies Series E announcement.
Company Info
Investors (6)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


